{
    "clinical_study": {
        "@rank": "139666", 
        "arm_group": [
            {
                "arm_group_label": "ejaculated sperm", 
                "arm_group_type": "Active Comparator", 
                "description": "Intracytoplasmic sperm injection (ICSI) cycles using ejaculated sperm"
            }, 
            {
                "arm_group_label": "testicular extracted sperm", 
                "arm_group_type": "Active Comparator", 
                "description": "Intracytoplasmic sperm injection (ICSI) cycles using testicular extracted sperm"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether couples undergoing IVF/ICSI with male\n      factor infertility, specifically with elevated sperm DNA damage, should testicular sperm\n      extraction be utilized to improve their reproductive outcomes."
        }, 
        "brief_title": "Testicular Versus Ejaculated Spermatozoa for IVF/ICSI in Men With High Sperm DNA Damage", 
        "completion_date": {
            "#text": "December 2011", 
            "@type": "Actual"
        }, 
        "condition": [
            "Infertility, Male", 
            "DNA Damage"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Infertility", 
                "Infertility, Male"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  \u226518 years of age\n\n          -  be considered infertile (>1 year of unsuccessful attempts of conception\n\n          -  Any race\n\n          -  Male partner with persistent sperm DNA damage, DFI>=30%\n\n          -  candidates for intracytoplasmic sperm injection (ICSI)\n\n        Exclusion Criteria:\n\n          -  significant female factor infertility contributing to the couple's infertility\n\n          -  female partner older than 38 years\n\n          -  male or female patients with genetic abnormalities\n\n          -  patients unable or unwilling to give consent after properly informed\n\n          -  couples unsuitable for IVF/ICSI\n\n          -  male patients in whom testicular procedures were contraindicated"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02058082", 
            "org_study_id": "Sperm DNA damage study"
        }, 
        "intervention": {
            "arm_group_label": [
                "ejaculated sperm", 
                "testicular extracted sperm"
            ], 
            "intervention_name": "Intracytoplasmic sperm injection", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Failure to Conceive Due to Infertility of Male Partner", 
            "DNA Damage"
        ], 
        "lastchanged_date": "February 6, 2014", 
        "number_of_arms": "2", 
        "official_title": "Randomized Control Trial on the Use of Testicular Versus Ejaculated Spermatozoa for IVF/ICSI on Pregnancy Outcomes for Men With High Sperm DNA Damage", 
        "overall_official": {
            "affiliation": "Mount Sinai Hospital, New York", 
            "last_name": "Kirk C. Lo, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Canada: Ethics Review Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Live birth rates", 
            "safety_issue": "No", 
            "time_frame": "Up to 1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02058082"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mount Sinai Hospital, Canada", 
            "investigator_full_name": "Kirk Lo", 
            "investigator_title": "Associate Professor, Division Urology Mount Sinai Hospital, University Toronto", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "sperm DNA damage", 
                "safety_issue": "No", 
                "time_frame": "Mesaured at baseline, 3 months  and on the day of Intracytoplasmic sperm injection (ICSI) procedure"
            }, 
            {
                "measure": "oocyte fertilization rates", 
                "safety_issue": "No", 
                "time_frame": "at approximately 18 hrs post Intracytoplasmic sperm injection (ICSI)"
            }, 
            {
                "measure": "embryo cleavage rate", 
                "safety_issue": "No", 
                "time_frame": "Day 3 post oocytes retrieval"
            }, 
            {
                "measure": "blastocyst rate", 
                "safety_issue": "No", 
                "time_frame": "Day 5 post oocytes retrieval"
            }, 
            {
                "description": "Clinical pregnancy was defined as the ultrasonographic visualization of one or more gestational sacs and fetal heart at the 6 to 8 week ultrasound", 
                "measure": "pregnancy rate", 
                "safety_issue": "No", 
                "time_frame": "6 to 8 week ultrasound"
            }, 
            {
                "measure": "rate of spontaneous abortion", 
                "safety_issue": "No", 
                "time_frame": "after a clinical pregnancy has been established, up to 10 months after procedure"
            }, 
            {
                "measure": "birth defects", 
                "safety_issue": "No", 
                "time_frame": "1-year following delivery"
            }
        ], 
        "source": "Mount Sinai Hospital, Canada", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mount Sinai Hospital, Canada", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2005", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}